Canada launches ambitious research portal

The Canadian Partnership Against Cancer has launched a research portal--the Canadian Partnership for Tomorrow Project (CPTP)--that includes health and biological data from 300,000 Canadians to help researchers study cancer and related chronic diseases.

"What makes the CPTP portal so valuable and unique is the volume and variety of the information that has been collected," said Heather Bryant, MD, PhD, vice president of cancer control at the partnership, in a release. "Researchers have access to health and lifestyle surveys, health outcome data and even biological samples like blood and toenail clippings. This lets them approach cancer and chronic disease from new angles, helping them dig deeper than ever before into its potential causes."

The data can be used to conduct long-term population health studies, which look at people's health, lifestyle or health risks. As study participants age, some may develop diseases such as cancer or heart disease. Researchers can then look back at their health data to search for factors that are linked to disease onset. These types of studies have pinpointed links between smoking and lung cancer, for example.

CPTP also will accelerate research, improve the competitiveness of Canadian research and provide opportunities for made-in-Canada discoveries.

In addition, the platform's wealth of information has been collected in a way that researchers worldwide can apply CPTP data to their own work or combine CPTP data with other global cohorts, allowing them to delve into rare cancers and chronic diseases as well.

"Given the complexity of cancer, we must study huge numbers of willing participants over a long period of time to uncover meaningful information about its risk factors. Thankfully, hundreds of thousands of Canadians have come forward to share their health information in hopes of unlocking the mystery of why some people develop cancer or other chronic diseases," said Paula Robson, PhD, scientific director at the Alberta Tomorrow Project, one of five provincial partners involved in CPTP.

CPTP is designed to track participants for 20 to 30 years, giving researchers even more data for their vital work.

Beth Walsh,

Editor

Editor Beth earned a bachelor’s degree in journalism and master’s in health communication. She has worked in hospital, academic and publishing settings over the past 20 years. Beth joined TriMed in 2005, as editor of CMIO and Clinical Innovation + Technology. When not covering all things related to health IT, she spends time with her husband and three children.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.